Reuters: Regulatory News: FDA to decide by March 17 on Pfizer/Bristol blood thinner

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

FDA to decide by March 17 on Pfizer/Bristol blood thinner Sep 26th 2012, 21:24 Sept 26 | Wed Sep 26, 2012 5:24pm EDT Sept 26 (Reuters) - U.S. health regulators set a date of March 17 to decide whether to approve a closely watched blood clot preventer developed by Bristol-Myers Squibb Co and Pfizer Inc for use in patients suffering from atrial fibrillation, the companies said on Wednesday. The U.S. Food and Drug Administration in June declined to approve the drug, Eliquis, and asked the companies to provide more information on a pivotal clinical trial of the medicine, which is designed to reduce the risk of stroke caused by blood clots in heart patients. Wall Street and the medical community widely expect approval of Eliquis, known chemically as apixaban, and see it becoming a major in an estimated $10 billion market for new alternatives to the decades old blood thinner warfarin.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions